FI111130B - Menetelmä syklosporiinijohdannaista sisältävän farmaseuttisen koostumuksen valmistamiseksi - Google Patents

Menetelmä syklosporiinijohdannaista sisältävän farmaseuttisen koostumuksen valmistamiseksi Download PDF

Info

Publication number: FI111130B
Authority: FI; Finland
Prior art keywords: weight; pharmaceutical composition; carrier medium; hydrophilic phase; composition
Prior art date: 1992-04-22

Application number

FI944978A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI944978A0 (fi

FI944978L (fi

Inventor

Jacky Vonderscher

Friedrich Richter

Armin Meinzer

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-22

Filing date

1994-10-21

Publication date

2003-06-13

1994-10-21 Application filed by Novartis Ag filed Critical Novartis Ag

1994-10-21 Publication of FI944978A0 publication Critical patent/FI944978A0/fi

1994-10-21 Publication of FI944978L publication Critical patent/FI944978L/fi

2003-06-13 Application granted granted Critical

2003-06-13 Publication of FI111130B publication Critical patent/FI111130B/fi

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
238000000034 method Methods 0.000 title claims description 20
238000002360 preparation method Methods 0.000 title claims description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title description 12
239000000203 mixture Substances 0.000 claims abstract description 57
229960001265 ciclosporin Drugs 0.000 claims abstract description 23
239000004530 micro-emulsion Substances 0.000 claims abstract description 21
239000004094 surface-active agent Substances 0.000 claims abstract description 19
235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 14
239000008158 vegetable oil Substances 0.000 claims abstract description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
-1 fatty acid ester Chemical class 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
239000004359 castor oil Substances 0.000 claims description 5
239000002285 corn oil Substances 0.000 claims description 5
235000005687 corn oil Nutrition 0.000 claims description 5
229920001214 Polysorbate 60 Polymers 0.000 claims description 4
235000019438 castor oil Nutrition 0.000 claims description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
239000007795 chemical reaction product Substances 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
238000010411 cooking Methods 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract description 8
208000011580 syndromic disease Diseases 0.000 abstract description 5
206010048723 Multiple-drug resistance Diseases 0.000 abstract description 2
229960000074 biopharmaceutical Drugs 0.000 abstract description 2
239000012071 phase Substances 0.000 description 14
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 10
229930182912 cyclosporin Natural products 0.000 description 10
108010036949 Cyclosporine Proteins 0.000 description 8
239000002775 capsule Substances 0.000 description 8
239000002609 medium Substances 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 6
108010036941 Cyclosporins Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
239000002253 acid Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
238000007127 saponification reaction Methods 0.000 description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000011630 iodine Substances 0.000 description 5
239000000654 additive Substances 0.000 description 4
239000012736 aqueous medium Substances 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
230000036457 multidrug resistance Effects 0.000 description 4
239000008389 polyethoxylated castor oil Substances 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
229930105110 Cyclosporin A Natural products 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 3
229940087168 alpha tocopherol Drugs 0.000 description 3
230000035622 drinking Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
229960000984 tocofersolan Drugs 0.000 description 3
235000004835 α-tocopherol Nutrition 0.000 description 3
239000002076 α-tocopherol Substances 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
239000003833 bile salt Substances 0.000 description 2
229940093761 bile salts Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
238000010586 diagram Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
235000013350 formula milk Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
238000010162 Tukey test Methods 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
230000036765 blood level Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000003255 drug test Methods 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
235000021149 fatty food Nutrition 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
238000002103 osmometry Methods 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
125000001020 α-tocopherol group Chemical group 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

FI944978A 1992-04-22 1994-10-21 Menetelmä syklosporiinijohdannaista sisältävän farmaseuttisen koostumuksen valmistamiseksi FI111130B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB9208712		1992-04-22
GB929208712A GB9208712D0 (en)	1992-04-22	1992-04-22	Pharmaceutical compositions containing cyclosporin derivates
EP9300955		1993-04-20
PCT/EP1993/000955 WO1993020833A1 (fr)	1992-04-22	1993-04-20	Composition pharmaceutique contenant un derive de cyclosporine

Publications (3)

Publication Number	Publication Date
FI944978A0 FI944978A0 (fi)	1994-10-21
FI944978L FI944978L (fi)	1994-10-21
FI111130B true FI111130B (fi)	2003-06-13

Family

ID=10714386

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI944978A FI111130B (fi)	1992-04-22	1994-10-21	Menetelmä syklosporiinijohdannaista sisältävän farmaseuttisen koostumuksen valmistamiseksi

Country Status (22)

Country	Link
EP (1)	EP0637248B1 (fr)
JP (1)	JP2818298B2 (fr)
KR (2)	KR950701227A (fr)
AT (1)	ATE219940T1 (fr)
AU (1)	AU672793B2 (fr)
CA (1)	CA2132740C (fr)
CY (1)	CY2399B1 (fr)
CZ (1)	CZ287359B6 (fr)
DE (1)	DE69332078T2 (fr)
DK (1)	DK0637248T3 (fr)
ES (1)	ES2179052T3 (fr)
FI (1)	FI111130B (fr)
GB (1)	GB9208712D0 (fr)
HU (1)	HU218279B (fr)
NO (1)	NO315075B1 (fr)
NZ (1)	NZ252681A (fr)
PT (1)	PT637248E (fr)
RU (1)	RU2126263C1 (fr)
SG (1)	SG50692A1 (fr)
SK (1)	SK282745B6 (fr)
UA (1)	UA34454C2 (fr)
WO (1)	WO1993020833A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
HK1004520A1 (en) *	1992-05-13	1998-11-27	Novartis Ag	Ophthalmic compositions containing a cyclosporin
PT589843E (pt)	1992-09-25	2002-04-29	Novartis Ag	Composicoes farmaceuticas contendo ciclosporinas
CH686761A5 (de) *	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
GB2278780B (en) *	1993-05-27	1998-10-14	Sandoz Ltd	Macrolide formulations
GB2315216B (en) *	1993-10-05	1998-10-14	Ciba Geigy Ag	Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
SK164796A3 (en)	1994-11-03	1997-06-04	Dresden Arzneimittel	Novel cyclosporine preparation forms for oral administration of and process for producing them
HU215966B (hu) *	1994-11-21	1999-07-28	BIOGAL Gyógyszergyár Rt.	Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
GB9601120D0 (en)	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
HU223054B1 (hu) *	1997-03-25	2004-03-01	BIOGAL Gyógyszergyár Rt.	Tisztítási eljárás nagytisztaságú ciklosporin A előállítására
ATE265847T1 (de) *	1997-07-29	2004-05-15	Upjohn Co	Selbstemulgierbare formulierung enthaltend lipophile verbindungen
HU228923B1 (en) *	1997-07-29	2013-06-28	Upjohn Co	Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
KR20010041623A (ko) *	1998-03-05	2001-05-25	니뽄 신야쿠 가부시키가이샤	흡입 투여용 지방 유제
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EA200301139A1 (ru)	2001-06-21	2004-12-30	Пфайзер Продактс Инк.	Самоэмульгирующиеся препараты ингибиторов белка-переносчика эфиров холестерина
IL160761A0 (en) *	2001-10-19	2004-08-31	Isotechnika Inc	Novel cyclosporin analog microemulsion preconcentrates
US6828301B2 (en)	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
RU2293763C2 (ru) *	2005-05-18	2007-02-20	Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова Российской академии медицинских наук (ГУ НИИВС им. И.И. Мечникова РАМН)	Способ получения акарицидно-моющего средства для борьбы с клещами
RU2294959C2 (ru) *	2005-05-18	2007-03-10	Общество с ограниченной ответственностью "Карат" (ООО "Карат")	Способ получения акарицидно-моющего средства для борьбы с клещами
RU2320365C2 (ru) *	2005-09-15	2008-03-27	Григорьев Лев Викторович	Фармацевтическая композиция
EP2204167A1 (fr)	2009-01-05	2010-07-07	Azad Pharma AG	Microémulsion pharmaceutique pour la prévention de l'agrégation supramoléculaire de molécules amphiphiles
MY154683A (en)	2009-07-07	2015-07-15	Boehringer Ingelheim Int	Pharmaceutical composition for a hepatitis c viral protease inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2907460A1 (de) *	1978-03-07	1979-09-13	Sandoz Ag	Neue resorbierbare galenische kompositionen
DE3884470T2 (de) *	1987-06-17	1994-03-10	Sandoz Ag	Cyclosporine und deren Benutzung als Arzneimittel.
PL155712B1 (en) *	1987-12-21	1991-12-31	Sandoz Ag	Method of obtaining novel crystalline form of cyclosporin
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물

1992
- 1992-04-22 GB GB929208712A patent/GB9208712D0/en active Pending
1993
- 1993-04-20 ES ES93911768T patent/ES2179052T3/es not_active Expired - Lifetime
- 1993-04-20 UA UA94105950A patent/UA34454C2/uk unknown
- 1993-04-20 CA CA002132740A patent/CA2132740C/fr not_active Expired - Fee Related
- 1993-04-20 SG SG1996008843A patent/SG50692A1/en unknown
- 1993-04-20 JP JP5517998A patent/JP2818298B2/ja not_active Expired - Fee Related
- 1993-04-20 EP EP93911768A patent/EP0637248B1/fr not_active Expired - Lifetime
- 1993-04-20 DK DK93911768T patent/DK0637248T3/da active
- 1993-04-20 PT PT93911768T patent/PT637248E/pt unknown
- 1993-04-20 SK SK1272-94A patent/SK282745B6/sk not_active IP Right Cessation
- 1993-04-20 AT AT93911768T patent/ATE219940T1/de not_active IP Right Cessation
- 1993-04-20 DE DE69332078T patent/DE69332078T2/de not_active Expired - Fee Related
- 1993-04-20 CZ CZ19942617A patent/CZ287359B6/cs not_active IP Right Cessation
- 1993-04-20 WO PCT/EP1993/000955 patent/WO1993020833A1/fr not_active Ceased
- 1993-04-20 RU RU94046413A patent/RU2126263C1/ru active
- 1993-04-20 NZ NZ252681A patent/NZ252681A/en not_active IP Right Cessation
- 1993-04-20 AU AU42611/93A patent/AU672793B2/en not_active Ceased
- 1993-04-20 HU HU9403055A patent/HU218279B/hu not_active IP Right Cessation
1994
- 1994-10-20 KR KR1019940703729A patent/KR950701227A/ko not_active Withdrawn
- 1994-10-21 NO NO19943998A patent/NO315075B1/no not_active IP Right Cessation
- 1994-10-21 FI FI944978A patent/FI111130B/fi active
2000
- 2000-12-08 KR KR10-2000-7013956A patent/KR100414853B1/ko not_active Expired - Fee Related
2003
- 2003-12-31 CY CY0300096A patent/CY2399B1/xx unknown

Also Published As

Publication number	Publication date
KR100414853B1 (fr)	2004-01-13
CZ287359B6 (en)	2000-11-15
CY2399B1 (en)	2004-09-10
NO943998D0 (no)	1994-10-21
WO1993020833A1 (fr)	1993-10-28
DK0637248T3 (da)	2002-10-28
JPH07505872A (ja)	1995-06-29
DE69332078T2 (de)	2002-12-19
GB9208712D0 (en)	1992-06-10
UA34454C2 (uk)	2001-03-15
RU2126263C1 (ru)	1999-02-20
CA2132740C (fr)	2008-01-15
AU672793B2 (en)	1996-10-17
KR950701227A (ko)	1995-03-23
FI944978A0 (fi)	1994-10-21
SG50692A1 (en)	1999-05-25
PT637248E (pt)	2002-11-29
ES2179052T3 (es)	2003-01-16
CZ261794A3 (en)	1995-02-15
HUT71580A (en)	1995-12-28
EP0637248B1 (fr)	2002-07-03
HU9403055D0 (en)	1994-12-28
CA2132740A1 (fr)	1993-10-28
NZ252681A (en)	1996-02-27
SK127294A3 (en)	1995-04-12
NO315075B1 (no)	2003-07-07
RU94046413A (ru)	1996-11-10
HU218279B (en)	2000-07-28
FI944978L (fi)	1994-10-21
JP2818298B2 (ja)	1998-10-30
SK282745B6 (sk)	2002-12-03
EP0637248A1 (fr)	1995-02-08
NO943998L (no)	1994-10-21
DE69332078D1 (de)	2002-08-08
AU4261193A (en)	1993-11-18
ATE219940T1 (de)	2002-07-15

Legal Events

Date	Code	Title	Description
1997-08-07	GB	Transfer or assigment of application	Owner name: NOVARTIS AG

Publication	Publication Date	Title
FI111130B (fi)	2003-06-13	Menetelmä syklosporiinijohdannaista sisältävän farmaseuttisen koostumuksen valmistamiseksi
US5980939A (en)	1999-11-09	Cyclosporin-containing pharmaceutical composition
JP3420897B2 (ja)	2003-06-30	医薬組成物
US5589455A (en)	1996-12-31	Cyclosporin-containing soft capsule compositions
EP1109532B1 (fr)	2005-03-02	Composition orale de silybine sous forme de microemulsion
EP0711550B1 (fr)	2002-01-16	Compositions pour capsule molle à base de cyclosporine
JP2662183B2 (ja)	1997-10-08	サイクロスポリン軟質カプセル剤組成物
HU223073B1 (hu)	2004-03-01	Ciklosporint tartalmazó gyógyszerkészítmény és eljárás annak előállítására
HUP0004379A2 (hu)	2001-08-28	Ciklosporin-tartalmú mikroemulziós elősürített kompozíciók
CA2362277C (fr)	2010-03-30	Compositions spontanement dispersibles de n-benzoyl staurosporine
EP0589843A1 (fr)	1994-03-30	Compositions pharmaceutiques comprenant de la cyclosporine
US20020049158A1 (en)	2002-04-25	Oral drug composition containing a verapamil derivative as a drug-absorption promotor
SK2482002A3 (en)	2002-12-03	Pharmaceutical compositions for oral and topical administration
EP0813876A1 (fr)	1997-12-29	Préparations contenant de cyclosporine pour capsules molles
US6028067A (en)	2000-02-22	Cyclosporin-containing microemulsion preconcentrate composition
KR100308779B1 (ko)	2001-11-15	사이클로스포린을함유한신규조성물
AP1040A (en)	2002-01-30	A novel composition containing cyclosporin.